Literature DB >> 11603811

Cortical Lewy body pathology in the diagnosis of dementia.

A J Harding1, G M Halliday.   

Abstract

Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) are distinguishable clinically but often not neuropathologically. This study aims to test whether the distribution of cortical Lewy bodies differs in these clinicopathological groups and to develop diagnostic protocols for their differentiation. Brains were obtained at autopsy from cases recruited from prospective clinical studies of dementia or movement disorders. All cases with significant pathologies other than Lewy bodies or plaques were excluded. Cases were categorised into either PD without dementia, DLB (dementia first or within 2 years of disease onset), or PD with a later onset of dementia (PDD). The distribution and density of Lewy bodies and Lewy neurites was determined using antibodies to ubiquitin and alpha-synuclein. Cortical Lewy body densities could not separate cases of DLB from those with PDD. However, semiquantitative thresholds in the parahippocampus could separate demented from non-demented cases with high sensitivity and specificity. Interactions between multiple pathologies were determined using factor analysis. Although many cases had CA2 Lewy neurites, this was not associated with severity or duration of either dementia or parkinsonism. Most DLB cases had significant plaque pathology, and severity and duration of dementia was related to both increasing parahippocampal Lewy body densities and neuritic plaque grade. Weighted kappa statistics revealed that the combination of these pathologies indicated a more severe dementia. These results suggest that dual pathologies cause DLB, and high densities of parahippocampal Lewy bodies indicate dementia regardless of additional pathologies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11603811     DOI: 10.1007/s004010100390

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  87 in total

1.  Cellular repair strategies in Parkinson's disease.

Authors:  Beate Winner; Daniela M Vogt-Weisenhorn; Chichung D Lie; Ingmar Blümcke; Jürgen Winkler
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

3.  PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies.

Authors:  Stephen N Gomperts; Marta Marquie; Joseph J Locascio; Stephen Bayer; Keith A Johnson; John H Growdon
Journal:  Neurodegener Dis       Date:  2015-12-08       Impact factor: 2.977

4.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

5.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

Review 6.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

7.  Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.

Authors:  Stephen N Gomperts; Joseph J Locascio; Dorene Rentz; Andrea Santarlasci; Marta Marquie; Keith A Johnson; John H Growdon
Journal:  Neurology       Date:  2012-12-12       Impact factor: 9.910

8.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

Review 9.  The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Authors:  Walter J Schulz-Schaeffer
Journal:  Acta Neuropathol       Date:  2010-06-20       Impact factor: 17.088

10.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.